Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-positive, HER2-negative Breast Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT03966898
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 426
Not applicableLooking for participantsNCT05878314
What this trial is testing

Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
University Hospital Tuebingen 504
Large-scale testing (Phase 3)Active Not RecruitingNCT04895358
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 342
Early research (Phase 1)Active Not RecruitingNCT06257264
What this trial is testing

Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Who this might be right for
Breast CancerSmall Cell Lung CancerOvarian Cancer+9 more
BeiGene 103
Large-scale testing (Phase 3)Not Yet RecruitingNCT06929325
What this trial is testing

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Who this might be right for
HR+/HER2- Advanced/Metastatic Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 312
Large-scale testing (Phase 3)Study completedNCT02692755
What this trial is testing

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Georgetown University 35
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Post-approval studies (Phase 4)Study completedNCT02679755
What this trial is testing

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 252
Not applicableLooking for participantsNCT07211178
What this trial is testing

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Tempus AI 900
Early research (Phase 1)Looking for participantsNCT07383506
What this trial is testing

Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Who this might be right for
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Cogent Biosciences, Inc. 90
Not applicableNot Yet RecruitingNCT07543250
What this trial is testing

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Who this might be right for
Breast Cancer
xuliang 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Large-scale testing (Phase 3)Study completedNCT03901339
What this trial is testing

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 543
Testing effectiveness (Phase 2)Looking for participantsNCT06341894
What this trial is testing

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Who this might be right for
Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 1,163
Testing effectiveness (Phase 2)Study completedNCT02732119
What this trial is testing

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 104
Testing effectiveness (Phase 2)Looking for participantsNCT06568692
What this trial is testing

PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast CancerHER2-negative Breast Cancer
Processa Pharmaceuticals 90
Early research (Phase 1)Study completedNCT06253195
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast Cancer+4 more
BeOne Medicines 33
Large-scale testing (Phase 3)Looking for participantsNCT07281833
What this trial is testing

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

Who this might be right for
Breast CancerHR-positive Breast CancerAdvanced Breast Cancer+2 more
Women's Cancer Study Group GmbH 250
Large-scale testing (Phase 3)UnknownNCT05439499
What this trial is testing

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Who this might be right for
Advanced Breast CancerFemale Breast Cancer
Ahon Pharmaceutical Co., Ltd. 434
Next Page